Oksitotsin-MEZ

General characteristics. Structure:

Active ingredient: 5 ME oxytocins of synthetic solution in 1 ml.

Excipients: chlorobutanol гемигидрат (хлоробутанолгидрат), acetic acid to pH 3,0-4,5, water for injections.

Pharmacological properties:

Pharmacodynamics. Hormonal means. Synthetic polypeptide analog of hormone of a back share of a hypophysis. Possesses the uterotoniziruyushchy, stimulating patrimonial activity and lactotropic action. Has a promoting effect on a myometrium (especially at the end of pregnancy, during patrimonial activity and directly during delivery).

Under the influence of oxytocin permeability of membranes for calcium increases, rest potential decreases and their excitability increases (reduction of membrane potential leads to increase in frequency, intensity and duration of reductions).

Oxytocin stimulates secretion of breast milk, strengthening production of prolactin a front share of a hypophysis. Reduces myoepithelial cells around alveoluses of a mammary gland, stimulates intake of milk to large canals or sine, promoting strengthening of department of milk.

It is almost deprived of vasopressor and antidiuretic action (only in high doses), does not cause reduction of muscles of a bladder and intestines.

The effect occurs in 1-2 min. at hypodermic and intramuscular introduction, 20-30 min. last; at intravenous - in 0,5-1 min., intranazalno - within several minutes.

Pharmacokinetics. Communication with proteins of plasma low (30%). It is metabolized in a liver and kidneys. During pregnancy in plasma, target organs, a placenta concentration of the oxytocinase inactivating endogenous and exogenous oxytocin increases. Removal generally kidneys in an invariable look. An elimination half-life of 1-6 min. (decreases on late durations of gestation and in the period of a lactation).

Indications to use:

For excitement and stimulation of patrimonial activity (primary and secondary weakness of patrimonial activity, need of early delivery in connection with a gestosis, a Rhesus factor conflict, pre-natal death of a fruit; postmature pregnancy, a premature bursting of waters, conducting childbirth in pelvic presentation).

For prevention and treatment of hypotonic uterine bleedings after abortion (including at big durations of gestation), in an early puerperal period and for acceleration of puerperal involution of a uterus; for strengthening of sokratitelny ability of a uterus at Cesarean section (after removal of an afterbirth).

Route of administration and doses:

Oxytocin is entered intravenously or intramusculary.

For initiation of childbirth enter intramusculary 0,5-2 ME oxytocins; if necessary repeat injections each 30-60 minutes.

For intravenous drop administration part 1 ml of synthetic oxytocin 5 ME in 500 ml of 5% of solution of a dextrose (glucose). Introduction is begun with 5-8 drops a minute, with the subsequent increase in speed depending on the nature of patrimonial activity (each 5-10 min. on 5 drops, but no more than 40 drops a minute).

For treatment of inevitable or incomplete abortion: intravenously kapelno, 10 ME oxytocins on 500 ml of 5% of solution of a dextrose with a speed of 20-40 thaws a minute.

For prevention of hypotonic uterine bleedings oxytocin is entered intramusculary on 3-5 ME 2-3 times a day daily within 2-3 days, and for treatment of hypotonic uterine bleedings entered 5-8 ME 2-3 times a day within 3 days.

Features of use:

Oxytocin is applied under control of sokratitelny activity of a uterus, a condition of a fruit, arterial pressure and the general condition of the woman.

Side effects:

Bradycardia (at mother and a fruit), a lowering of arterial pressure, shock or increase in arterial pressure and subarachnoidal bleeding, disturbances of a heart rhythm (including at a fruit); bronchospasm; nausea, vomiting, a water delay, neonatal jaundice, decrease in concentration of fibrinogen at a fruit, allergic reactions, and also excessively vigorous patrimonial activity that can cause an acute hypoxia of a fruit, premature amotio of normally located placenta, a hysterorrhesis.

At emergence of symptoms of these complications it is necessary to stop administration of drug immediately.

Interaction with other medicines:

With care apply oxytocin in a combination with sympathomimetics (exponentiates pressor action of sympathomimetics).

The halothane and cyclopropane strengthen risk of development of arterial hypotension.

Contraindications:

Hypersensitivity, narrow basin (anatomic and clinical), the cross or slanting provision of a fruit, front presentation, premature births, predisposition to a hysterorrhesis, hems on a uterus (after the postponed earlier Cesarean section or other uterus operations), uterus hyperdystension, a uterus after repeated childbirth, partial placental presentation, uterine sepsis, an invasive carcinoma of a neck of uterus, the uterus hyper tone (which arose not during childbirth), a fruit prelum, arterial hypertension, a chronic renal failure, suspicion on premature placental detachment, a pre-natal hypoxia of a fruit.

Overdose:

Hyper stimulation of a uterus that can lead to a hyper tone and tetanic reductions of a uterus which in turn can lead to a hysterorrhesis, puerperal bleeding, various changes from cordial activity of a fruit, a hypoxia and death of a fruit.

At prolonged use of oxytocin in high doses by infusion (40-50 ml/min.) there can be symptoms connected with antidiuretic effect of oxytocin.

At overdose it is necessary to stop immediately introduction of oxytocin, to force a diuresis, to administer the symptomatic drugs and hypertonic saline solutions (for the purpose of normalization of electrolytic balance).

Storage conditions:

In the place protected from light at a temperature from 8 to 20 °C. To store in the places unavailable to children. A period of validity - 3 years. Not to apply until expiry date, specified on packaging.

Issue conditions:

According to the recipe

Packaging:

Solution for intravenous and intramuscular administration, 5 ME/ml. Packaging: on 1 ml of drug in ampoules of neutral glass of the NS-1 brand or import. On 5 ampoules in a blister strip packaging from a film polyvinyl chloride and a foil of the aluminum printing varnished or flexible packaging on the basis of aluminum foil, or without foil. On 1 or 2 blister strip packagings (with a foil or without foil) with the application instruction of drug, a knife or the scarificator ampoule in a pack from a cardboard. On 20, 50 or 100 blister strip packagings (with a foil) with 20, 50 or 100 application instructions of drug respectively, knives or scarificators ampoule in boxes from a cardboard or in boxes from corrugated fibreboard (for a hospital). When packaging ampoules with notches, rings and points of a break knives or scarificators ampoule do not put.